Paracrine Receptor Activation by Microenvironment Triggers Bypass Survival Signals and ALK Inhibitor Resistance in EML4-ALK Lung Cancer Cells

Tadaaki Yamada1, Shinji Takeuchi1, Junya Nakade1, Kenji Kita1, Takayuki Nakagawa1,2, Shigeki Nanjo1, Takahiro Nakamura3, Kunio Matsumoto3, Manabu Soda4, Hiroyuki Mano4, Toshimitsu Uenaka2, and Seiji Yano1

Abstract

Purpose: Cancer cell microenvironments, including host cells, can critically affect cancer cell behaviors, including drug sensitivity. Although crizotinib, a dual tyrosine kinase inhibitor (TKI) of ALK and Met, shows dramatic effect against EML4-ALK lung cancer cells, these cells can acquire resistance to crizotinib by several mechanisms, including ALK amplification and gatekeeper mutation. We determined whether microenvironmental factors trigger ALK inhibitor resistance in EML4-ALK lung cancer cells.

Experimental Design: We tested the effects of ligands produced by endothelial cells and fibroblasts, and the cells themselves, on the susceptibility of EML4-ALK lung cancer cell lines to crizotinib and TAE684, a selective ALK inhibitor active against cells with ALK amplification and gatekeeper mutations, both in vitro and in vivo.

Results: EML4-ALK lung cancer cells were highly sensitive to ALK inhibitors. EGF receptor (EGFR) ligands, such as EGF, TGF-α, and HB-EGF, activated EGFR and triggered resistance to crizotinib and TAE684 by transducing bypass survival signaling through Erk1/2 and Akt. Hepatocyte growth factor (HGF) activated Met/Gab1 and triggered resistance to TAE684, but not crizotinib, which inhibits Met. Endothelial cells and fibroblasts, which produce the EGFR ligands and HGF, respectively, decreased the sensitivity of EML4-ALK lung cancer cells to crizotinib and TAE684, respectively. EGFR-TKIs resensitized these cells to crizotinib and Met-TKI to TAE684 even in the presence of EGFR ligands and HGF, respectively.

Conclusions: Paracrine receptor activation by ligands from the microenvironment may trigger resistance to ALK inhibitors in EML4-ALK lung cancer cells, suggesting that receptor ligands from microenvironment may be additional targets during treatment with ALK inhibitors. Clin Cancer Res; 1–11. ©2012 AACR.

Introduction

ALK fusion with EML4 in non–small cell lung cancer (NSCLC) was first detected in 2007 (1), with 3% to 7% of unselected NSCLCs having this fusion gene (1–4). EML4-ALK lung cancer is more frequently observed in patients with adenocarcinoma than with other histologies, in young adults than in older patients, and in never-smokers or light smokers (<15 pack-years) than in heavier smokers (2, 3). ALK kinase inhibitors show dramatic effects against lung cancers with EMK4-ALK in vitro and in vivo (3, 4). In a phase I–II trial with crizotinib, a dual tyrosine kinase inhibitor (TKI) of ALK and Met, the overall response rate was 47 of 82 (57%) patients with EML4-ALK–positive tumors (5). However, almost all patients who show a marked response to ALK-TKIs acquire resistance to these agents after varying periods of time (6, 7). Secondary mutations, including the gatekeeper L1196M mutation and others (F1174L, C1156Y, G1202R, S1206Y, 1151-T-ins, and G1269A), ALK amplification, KIT amplification, and autophosphorylation of EGF receptor (EGFR), were shown to be responsible for acquired resistance to crizotinib in ALK–translocated cancers (6–10).

Selective ALK inhibitors, including TAE684 and CH5424802, have been reported active against EML4-ALK lung cancer cells with ALK amplification and secondary mutations. These cells, however, may develop resistance to this class of inhibitor, due to several mechanisms, including novel ALK mutations (L1152R, L1198P, and D1203N), coactivation of EGFR and ErbB2, and EGFR phosphorylation (3, 11, 12).
Translational Relevance

Although crizotinib, a dual inhibitor of ALK and Met, shows dramatic effects against EML4-ALK lung cancer cells, these cells can acquire resistance by several mechanisms, including ALK amplification and gatekeeper mutation. Selective ALK inhibitors may overcome crizotinib resistance due to these mechanisms, but these cells may become resistant to these inhibitors.

We show here that EGF receptor ligands produced by endothelial cells can cause EML4-ALK lung cancer cells to become resistant to crizotinib and selective ALK inhibitors by triggering bypass survival signals. By contrast, hepatocyte growth factor produced by fibroblasts can induce resistance to selective ALK inhibitors, but not crizotinib. Because endothelial cells and fibroblasts are components of the microenvironment, our findings raise clinical questions about the class of ALK inhibitors more beneficial for EML4-ALK lung cancer patients. Moreover, our results provide a rationale for targeting receptor ligands in the microenvironment for more successful treatment with ALK inhibitors.

Materials and Methods

Cell culture

The H2228 human lung adenocarcinoma cell line, with the EML4-ALK fusion protein variant3 (E6;A20), the umbilical vein endothelial cell line human umbilical vein endothelial cells (HUVEC) and the human bronchial epithelial cell line BEAS-2B, transformed with SV40 virus, were purchased from the American Type Culture Collection. The H3122 human lung adenocarcinoma cell line, with the EML4-ALK fusion protein variant1 (E13;A20), was kindly provided by Dr. Jeffrey A. Engelman of the Massachusetts General Hospital Cancer Center, Boston, MA (3). The MANA2 mouse lung adenocarcinoma cell line was established in Jichi Medical University from a tumor nodule developed in a transgenic mouse expressing EML4-ALK variant 1 (E13;A20) (23). The MRC-5 and IMR-90 lung embryonic fibroblast cell lines were obtained from RIKEN Cell Bank. The human dermal microvessel endothelial cell line HMVEC was purchased from Kurabo. The monocytic leukemia cell line U937 was purchased from Health Science Research Resources Bank. H2228 cells were cultured in RPMI-1640 medium, MANA2 cells were cultured in DMEM/F12 + GlutaMAX-1, and MRC-5 (P 25–30) cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) medium, supplemented with 5% fetal bovine serum, penicillin (100 U/mL), and streptomycin (50 µg/mL). In a humidified CO₂ incubator at 37°C. HMVECs and HUVECs were maintained in HuMedia-MvG with growth supplements (Kurabo) and used for in vitro assays at passages 2 to 5 and 2 to 4, respectively. BEAS-2B cells were maintained in LHC9/RPMI-1640 medium, as described (24), and used for in vitro assays at passages 42 to 46. Macrophage differentiation of U937 cells was induced by incubation in RPMI-1640 medium containing 10 ng/mL phorbol 12-myristate 13-acetate (Sigma Chemical Co.; ref. 25) for 5 days, with floating cells removed by rinsing with PBS, as described (26). Differeniatied U937 cells (PMA-U937 cells) attached to the dishes were used for in vitro assays at passages 6 to 8. All cells were passaged for less than 3 months before renewal from frozen, early-passage stocks obtained from the indicated sources. Cells were regularly screened for Mycoplasma using a MycoAlert Mycoplasma Detection Kit (Lonza).

Reagents

TAE684, crizotinib, and WZ4002 were purchased from Selectek Chemicals. Erlotinib hydrochloride was obtained from Chugai Pharmaceutical Co., Ltd. The anti-human EGF antibody cetuximab was obtained from Merck Serono. E7050 was synthesized by Eizai Co., Ltd. (27). Goat anti-human HGF antibody, control goat IgG, recombinant EGF, TGF-α, HB-EGF, IGF-1, and PDGF-AA were purchased from R&D Systems. Recombinant HGF was prepared as described (28).
Cell growth assay

Cell proliferation was measured using the MTT dye reduction method (17). Tumor cells at 80% confluence were harvested, seeded at 2 x 10^3 cells per well in 96-well plates, and incubated in appropriate medium for 24 hours. Several concentrations of TAE684, crizotinib, erlotinib, WZ4002, E7050, cetuximab, anti-HGF antibody, and/or EGF, TGF-α, HB-EGF, IGF-1, PDGF-AA, and HGF were added to each well, and incubation was continued for a further 72 hours. To each well was added 50μL MTT (2 mg/mL, Sigma), followed by incubation for 2 hours at 37°C. The media were removed and the dark blue crystals in each well were dissolved in 100 μL of dimethyl sulfoxide (DMSO). Absorbance was measured with an MTP-120 Microplate reader (Corona Electric) at test and reference wavelengths of 550 and 630 nm, respectively. The percentage growth was calculated relative to untreated controls. Each assay was carried out at least in triplicate, with results based on 3 independent experiments.

Apoptosis assay

H2228 and H3122 cells (3 x 10^6 cells) were seeded in 96-well, white-walled plates and incubated overnight. The cells were treated with crizotinib (1 μmol/L) or vehicle (DMSO) for 48 hours. Cellular apoptosis was determined by measuring caspase-3/7 activity using a luminometric Caspase-Glo 3/7 assay (Promega) according to the manufacturer’s protocol, with luminescence intensity measured using a Fluoroskan Ascent FL plate reader (Thermo Scientific). Cellular apoptosis was expressed relative to DMSO-treated control cells.

RNA interference

Duplexed Stealth RNAi (Invitrogen) against EGF, Met, ErbB3, Gab1, ALK, and Stealth RNAi-negative control low GC Duplex #3 (Invitrogen) were used for RNA interference (RNAi) assays. Briefly, aliquots of 1 x 10^5 cells in 2 mL of antibiotic-free medium were plated into each well of a 6-well plate and incubated at 37°C. These tumor cells were then used for cell proliferation assays, with EGF (10 ng/mL), or HGF (50 ng/mL) for an additional 48 hours in antibiotic-containing medium. The concentrations of TAE684, crizotinib (100 nmol/L), TAE684 (100 nmol/L), recombinant human EGF (100 ng/mL), TGF-α (100 ng/mL), HB-EGF (10 ng/mL), or HGF (50 ng/mL) for an additional 48 hours in antibiotic-containing medium. These tumor cells were then used for cell proliferation assays, with EGF, Met, ErbB3, Gab1, and ALK knockdowns (#1, #2) confirmed by Western blotting.

The siRNA target sequences were as follows: EGF (C26G7), anti-phospho-ALK (Tyr1604), anti-phospho-EGFR (Tyr1068), anti STAT-3 (79D7), anti-phospho-STAT-3 (Y705), anti-Akt, anti-phospho-Akt (Ser473), anti-ErbB4 (111B2), anti-EGFR (1284), anti Met (2SH2), anti-phospho-Met (Y1234/Y1235) (3D7), anti Gab1 (#3232), anti-phospho-Gab1 (Tyr627) (C32H2), anti ErbB3 (1B2), anti-phospho-ErbB3 (Tyr1289) (21D3), or anti-β-actin (13E5) antibodies (1:1000 dilution each; Cell Signaling Technology), or with anti-human EGFR (1 μg/mL), anti-human/mouse/rat extracellular signal-regulated kinase (Erk) 1/Erk2 (0.2 μg/mL), or anti-phospho-Erk1/Erk2 (T202/Y204) (0.1 μg/mL) antibodies (R&D Systems). After washing 3 times, the membranes were incubated for 1 hour at room temperature with secondary Ab (horseradish peroxidase-conjugated species-specific Ab). Immunoreactive bands were visualized with SuperSignal West Dura Extended Duration Substrate Enhanced Chemiluminescent Substrate (Pierce). Each experiment was carried out at least 3 times independently.

Western blotting

SDS polyacrylamide gels (Bio-Rad) were loaded with 40 μg total protein per lane; following electrophoresis, the proteins were transferred onto polyvinylidene difluoride membranes (Bio-Rad), which were incubated with Blocking One (Nacalai Tesque) for 1 hour at room temperature, followed by overnight incubation at 4°C with anti-ALK (C26G7), anti-phospho-ALK (Tyr1604), anti-phospho-EGFR (Tyr1068), anti-STAT3 (79D7), anti-phospho-STAT3 (Y705), anti-Akt, anti-phospho-Akt (Ser473), anti-ErbB4 (111B2), anti-EGFR (1284), anti Met (2SH2), anti-phospho-Met (Y1234/Y1235) (3D7), anti Gab1 (#3232), anti-phospho-Gab1 (Tyr627) (C32H2), anti ErbB3 (1B2), anti-phospho-ErbB3 (Tyr1289) (21D3), or anti-β-actin (13E5) antibodies (1:1000 dilution each; Cell Signaling Technology), or with anti-human EGFR (1 μg/mL), anti-human/mouse/rat extracellular signal-regulated kinase (Erk) 1/Erk2 (0.2 μg/mL), or anti-phospho-Erk1/Erk2 (T202/Y204) (0.1 μg/mL) antibodies (R&D Systems). After washing 3 times, the membranes were incubated for 1 hour at room temperature with secondary Ab (horseradish peroxidase-conjugated species-specific Ab). Immunoreactive bands were visualized with SuperSignal West Dura Extended Duration Substrate Enhanced Chemiluminescent Substrate (Pierce). Each experiment was carried out at least 3 times independently.

HGF, EGF, TGF-α, and HB-EGF production in cell culture supernatant

Cells (2 x 10^6) were cultured in 2 mL of RPMI-1640 or DMEM with 5% FBS for 24 hours. The cells were washed with PBS and incubated for 48 hours in RPMI-1640 or DMEM with 5% FBS. The culture medium was harvested and centrifuged, and the supernatant was stored at −70°C until analysis. HGF (Immunis HGF ELISA; B-Bridge International), EGF, TGF-α, and HB-EGF (Quantikine ELISA kits; R&D Systems) were assayed by ELISA, in accordance with the manufacturer’s procedures. All samples were run in triplicate. Color intensity was measured at 450 nm with a spectrophotometric plate reader. Growth factor concentrations were determined by comparison with standard curves. The detection limits for HGF, EGF, TGF-α, and HB-EGF were 0.1 ng/mL, 3.9 pg/mL, 15.6 pg/mL, and 31.2 pg/mL, respectively.

Coculture of lung cancer cells with fibroblasts or endothelial cells

Cells were cocultured in Transwell Collagen-Coated chambers separated by an 8-μm (BD Biosciences, Erembodegem) or 3-μm (Corning Costar) pore size filter. Tumor cells (8 x 10^5 cells/800 μL) with or without TAE684...
(100 nmol/L) or crizotinib (100 nmol/L) in the lower chamber were cocultured with MRC-5 (1 × 10^4 cells/300 µL) or HMVEC (1 × 10^6 cells/300 µL) cells, with or without 2 hours of pretreatment with anti-human HGF antibody (2 µg/mL) or cetuximab (2 µg/mL) in the upper chamber for 72 hours. The upper chamber was then removed, 200 µL of MTT solution (2 mg/mL, Sigma) was added to each well and the cells were incubated for 2 hours at 37°C. The media were removed and the dark blue crystals in each well were dissolved in 400 µL of DMSO. Absorbance was measured with an MTP-120 Microplate reader (Corona Electric) at test and reference wavelengths of 550 and 630 nm, respectively. The percentage growth was measured relative to untreated controls. All samples were assayed at least in triplicate, with each experiment conducted 3 times independently.

**Xenograft studies in SCID mice**

Suspensions of H2228 cells (5 × 10^6), with or without MRC-5 cells (5 × 10^6), were injected subcutaneously into the backs of 5-week-old male severe combined immunodeficient (SCID) mice (Japan Clea). After 4 days (tumors diameter >4 mm), mice were randomly allocated into groups of 6 animals to receive TAE684 (1.25 mg/kg/d) or vehicle by oral gavage. Tumor size was measured with digital calipers, and tumor volume was calculated as 0.5 × length × (width)^2. All animal experiments complied with the Guidelines for the Institute for Experimental Animals, Kanazawa University Advanced Science Research Center (approval no. AP-081088).

**HGF production in tumor tissues**

Tumors obtained from SCID mice after 4 and 8 days were lysed in mammalian tissue lysis buffer containing a phosphatase and proteinase inhibitor cocktail (Sigma). HGF was quantitated by ELISA (Immunis HGF EIA; Institute of Immunology), with a detection limit of 0.1 ng/mL. All samples were assayed in triplicate.

**Statistical analysis**

Differences were analyzed by one-way ANOVA. All statistical analyses were carried out using GraphPad Prism Ver.4.01 (GraphPad Software, Inc.). P < 0.05 was considered significant.

**Results**

**HGF and/or EGFR ligands reduced the sensitivity of EML4-ALK lung cancer cells to ALK inhibitor in vitro**

We first examined the sensitivity of human H2228, human H3122, and mouse MANA2 lung cancer cell lines, all containing EML4-ALK translocations, to the ALK inhibitors crizotinib and TAE684, and to various EGFR-TKIs. Human H2228 cells with EML4-ALK variant 3 (E6;A20) and H3122 cells with EML4-ALK variant 1 (E13;A20) were insensitive to the EGFR-TKIs erlotinib (a reversible EGFR-TKI) and WZ4002 (selective for mutant EGFR), but sensitive to the ALK-TKIs crizotinib and TAE684 (Fig. 1). MANA2 cells, established from lung tumors of an EML4-ALK variant 1 (E13;A20) transgenic mouse, were also sensitive to crizotinib and TAE684, although their viability was slightly inhibited by high concentrations (1 µmol/L) of EGFR-TKIs.

Because several growth factors have been associated with poor patient prognosis and/or drug resistance in lung cancer, we explored the effect of EGFR ligands (EGF, TGF-α, and HB-EGF), IGF-1, PDGF-AA, and HGF on the sensitivity of EML4-ALK lung cancer cells to ALK inhibitors.

In the absence of ALK inhibitors, these growth factors slightly increased the viability of H2228, H3122, and MANA2 cells. In H2228 cells, all 3 EGFR ligands reduced sensitivity to crizotinib in a dose-dependent manner, but IGF-1, PDGF-AA, and HGF failed to do so (Fig. 2, Supplementary Fig. S1). Interestingly, HGF, as well as the EGFR ligands, reduced sensitivity to TAE684, but IGF-1 and PDGF-AA failed to do so. Similar results were observed in H3122 and MANA2 cells. To further confirm the effect of these growth factors on specific ALK inhibition, we knocked down ALK using 2 different specific siRNAs in H2228 cells. Whereas H2228 cells were highly sensitive to ALK-specific siRNAs, EGFR ligands and HGF restored cell viability inhibited by ALK knockdown (Supplementary Fig. S2). When we...
assessed the ability of crizotinib to induce apoptosis in H2228 and H3122 cells, we found that crizotinib induced apoptosis in H3122, but not H2228, cells (Supplementary Fig. S3).

HGF and EGFR ligands trigger ALK inhibitor resistance via Met and EGFR, respectively

To assess the mechanism by which these growth factors reduced cell sensitivity to ALK inhibitors, we analyzed the phosphorylation status of ALK, receptors, and their downstream molecules in H2228, H3122, and MANA2 cells by Western blotting. Crizotinib inhibited ALK phosphorylation, thereby suppressing the phosphorylation of Akt, Erk1/2 and STAT-3, as described (ref. 11; Fig. 3A, Supplementary Fig. S4). The EGFR ligands, EGF, TGF-α, and HB-EGF stimulated EGFR phosphorylation. Crizotinib inhibited ALK and STAT-3 phosphorylation even in the presence of EGFR ligands, but failed to inhibit phosphorylation of EGFR and downstream Akt, and Erk1/2. Phosphorylation of ErbB4, a potential receptor for HB-EGF, was not affected by crizotinib or EGFR ligands. To further confirm the involvement of EGFR in crizotinib resistance induced by EGFR ligands, we knocked down EGFR by specific siRNAs in H2228 and H3122 cells (Fig. 3B). Although crizotinib markedly inhibited cell viability and all 3 EGFR ligands induced resistance in cells treated with scrambled siRNA, resistance to crizotinib was not induced by EGF, TGF-α, or HB-EGF in EGFR siRNA-treated cells, indicating that EGFR ligand-triggered crizotinib resistance is mediated by EGFR.

In parallel experiments, TAE684 inhibited ALK phosphorylation, thereby suppressing the phosphorylation of Akt, Erk1/2, and STAT-3 (Fig. 3C). HGF stimulated the phosphorylation of Met and its adaptor protein, Gab1, as described (29). TAE684 inhibited ALK and STAT-3 phosphorylation even in the presence of HGF, but failed to inhibit phosphorylation of Met and downstream Akt and Erk1/2. Phosphorylation of ErbB3, an adaptor of amplified, but not HGF-stimulated Met (30), was not affected by TAE684 or HGF. To further confirm the involvement of Met and Gab1 in HGF-induced resistance to TAE684, we knocked down Met, ErbB3, or Gab1 by specific siRNAs in H2228 and H3122 cells (Fig. 3D). TAE684 markedly inhibited the viability and HGF induced resistance in cells treated with scrambled siRNA. Importantly, treatment of cells with Met or Gab1, but not ErbB3, siRNA, induced TAE684 resistance, indicating the involvement of Met/Gab1 in HGF-induced resistance to TAE684.

Cross-talk of endothelial cells and fibroblasts reduces the sensitivity of EML4-ALK lung cancer cells to ALK inhibitors

To determine which types of host cells could produce EGFR ligands and HGF, we investigated production of these growth factors by various types of host stromal cells, comparing lung epithelial cells and cancer cells. The endothelial cell lines HMVEC produced discernible levels of EGFR ligands, including EGF, TGF-α, and HB-EGF, whereas fibroblasts produced a high level of HGF (Fig. 4A). EML4-ALK lung cancer cells (H2228, H3122, and...
MANA2) and lung epithelial cells (BEAS-2B) produced low or no detectable levels of EGFR ligands or HGF. Interestingly, coculture of H2228 or H3122 cells with fibroblasts (MRC-5) significantly reduced their sensitivity to TAE684, an effect abrogated by anti-HGF antibody (Fig. 4B). Coculture with endothelial cells (HMVEC) also reduced sensitivity to crizotinib, an effect inhibited by anti-EGFR antibody (Fig. 4C).

These results suggested that host stromal cells, such as endothelial cells and fibroblasts, may regulate sensitivity to ALK inhibitors by secreting EGFR ligands and HGF, respectively.

HGF derived from fibroblasts induces TAE684 resistance of EML4-ALK lung cancer cells in vivo

To investigate whether sensitivity to TAE684 could be affected by fibroblasts in vivo, we subcutaneously inoculated H2228 cells, with or without MRC-5 cells, into SCID mice. The tumors of mice injected with H2228 and MRC-5 cells grew slightly faster than those of mice injected with
H2228 cells alone, but the difference was not statistically significant by day 8 (Fig. 5A). TAE684 treatment, beginning on day 4, caused marked regression of tumors in mice injected with H2228 cells alone, but not of tumors in mice injected with H2228 and MRC-5 cells, indicating that fibroblasts induced resistance to TAE684 in vivo (Fig. 5A). We confirmed that HGF was produced by MRC-5 cells in vivo. Although the tumors of mice injected with H2228 cells alone did not produce detectable levels of HGF, the tumors of mice injected with H2228 and MRC-5 cells produced high levels of HGF, started on day 4, but decreasing slightly on day 8 (Fig. 5B).

We further analyzed whether co-injection of MRC-5 cells restored the Akt pathway inhibited by TAE684 in the tumors. Western blotting showed that TAE684 treatment inhibited Akt phosphorylation, which was restored by coinjection of MRC-5 cells (Fig. 5C). These results suggested that fibroblasts produced HGF in the tumors and restored Akt phosphorylation as a survival signal, as well as inducing resistance to TAE684 in EML4-ALK lung cancer cells in vivo.

**Ligand-triggered resistance to ALK inhibitors is abrogated by inhibitors of both HGF-Met and EGFR**

To establish novel strategies to treat EGFR ligand- or HGF-triggered resistance to ALK inhibitors, we examined the effect of combinations of ALK inhibitors with EGFR inhibitors (anti-EGFR Abs and reversible EGFR-TKIs) and HGF-Met inhibitors (anti-HGF Abs and Met-TKIs). Combined treatment with erlotinib, a reversible EGFR-TKI and cetuximab, an anti-EGFR Ab, successfully resensitized H2228 and H3122 cells to crizotinib even in the presence of HGF and HGF-Met. Moreover, the combination of HGF with E7050 (Met-TKI) or anti-HGF Ab resensitized cells to TAE684 (Fig. 6D).

![Figure 4](https://example.com/figure4.png)
Discussion

We have shown here that endothelial cells and fibroblasts, both components of the tumor microenvironment, secreted EGFR ligands and HGF, respectively, causing resistance to the ALK inhibitors crizotinib and/or TAE684 by activating bypass survival signals.

Of the EGFR ligands, EGF and TGF-α bind predominantly to EGFR, whereas HB-EGF binds to EGFR and ErbB4 (17). H2228 cells expressed both EGFR and ErbB4. Our results suggested that the bypass survival signal induced by EGFR ligands is mediated mainly by EGFR, as EGFR ligands markedly activated the phosphorylation of EGFR, not ErbB4. Moreover, knockdown of EGFR abrogated resistance caused by all EGFR ligands tested. EGFR ligand–triggered resistance was canceled by erlotinib or cetuximab, an anti-EGFR Ab, drugs approved for the treatment of patients with NSCLC and colorectal cancer. In addition, AP26113, an inhibitor of both ALK and EGFR, has been reported active against EML4-ALK lung cancer cells with amplified ALK and secondary mutations (7). Therefore, clinical trials are warranted to evaluate the efficacy and feasibility of combinations of an ALK inhibitor and these EGFR inhibitors to overcome ALK inhibitor resistance.

HGF, the sole ligand of Met (29), is important in EGFR-TKI resistance in EGFR-mutant lung cancer. HGF derived from cancer cells or stromal fibroblasts activated Met phosphorylation and stimulated the downstream Akt and Erk1/2 pathways (21, 22, 30) using Gab1, an adaptor protein for Met (31), triggering resistance to both reversible and irreversible EGFR-TKIs. In our Japanese cohort study of patients with EGFR-mutant lung cancer, high HGF expression was detected in 61% of tumors with acquired resistance and in 29% of tumors with intrinsic resistance to EGFR-TKIs, suggesting the rationale of targeting HGF to overcome EGFR-TKI resistance (32). We also found that HGF triggered TAE684 resistance by activating Met and stimulating downstream Akt and Erk1/2 pathways using the adaptor protein Gab1. Because many anti-HGF Abs and Met-TKIs are being evaluated in clinical trials, HGF-triggered resistance to selective ALK inhibitors may be controlled by their combinations in the near future.

EGFR and Met have been shown to interact with each other and to mediate redundant signaling in lung cancer cells (33). In EGFR-mutant lung cancer cells, Met amplification causes EGFR-TKI resistance by triggering bypass survival signals using ErbB3, an adaptor protein (34). Met activation by HGF also triggers resistance to EGFR-TKIs that use Gab1 as an adaptor. In EML4-ALK lung cancer cells, both novel ALK second mutations and autocrine EGFR activation causes resistance to ALK inhibitors (11). We found that paracrine HGF and EGFR ligands could trigger ALK inhibitor resistance. Taken together, these findings suggest that signaling by EGFR and Met is crucial for the survival of lung cancer cells with EGFR mutations and EML4-ALK translocations under inhibition of these driver oncogenes.

We found that resistance to TAE684 was induced by both EGFR ligands and HGF, whereas crizotinib resistance was induced by EGFR ligands alone, a finding that may be due to the dual activities of crizotinib on ALK and...
Met (5). Selective ALK inhibitors are expected to be effective against EML4-ALK lung cancer cells, even after acquiring ALK amplification and ALK second mutations and becoming refractory to crizotinib (7, 35). Our findings, however, suggest that HGF-triggered resistance may be directed against selective ALK inhibitors, not crizotinib. Future clinical trials with selective ALK inhibitors may reveal the class of ALK inhibitors that is more beneficial for EMK4-ALK lung cancer patients.

EML4-ALK- and EGFR-mutant lung cancers show dramatic responses to ALK inhibitors and EGFR-TKIs, respectively (5, 36, 37). Complete responses, however, are rarely achieved, despite these cells express the target (EML4-ALK or mutant EGFR) of the drug. Low expression of BIM, a proapoptotic molecule, may explain, at least in part, the variations in sensitivity of EGFR-mutant lung cancer to EGFR-TKIs (38). This heterogeneous sensitivity may also be explained by HGF, as HGF is expressed more or less equally in EGFR-mutant lung tumors sensitive to EGFR-TKIs (32). Therefore, EGFR ligands in EML4-ALK lung tumors may be involved in their heterogeneous response to crizotinib. It is also curious whether ligand-triggered resistance is an independent mechanism or one that provided partial resistance when combined with another mechanism. Because crizotinib is expected to be approved in Japan to treat EML4-ALK lung cancer in 2012, we are planning a study to assess this possibility in clinical specimens.

In conclusion, we found that receptor ligands, such as EGFR ligands and HGF, could cause resistance to the ALK inhibitors crizotinib and/or TAE684 by activating bypass survival signals. These ligands and growth factors may be produced by host stromal cells, which constitute the cancer microenvironment. Paracrine HGF from stromal fibroblasts may also trigger resistance to EGFR-TKIs in EGFR-mutant lung cancer cells by activating bypass signals (22). Collectively, these observations suggest that paracrine receptor activation by the microenvironment...
may be an important mechanism inducing resistance to molecular targeted drugs in oncogene-activated lung cancer cells. These findings suggest that targeting of receptor ligands may result in more successful therapy in lung cancer.

**Disclosure of Potential Conflicts of Interest**

S. Yano received honoraria from Chugai Pharma and AstraZeneca and research fundings from Chugai Pharma and Eisai co., Ltd. H. Mano received honoraria from Pfizer Inc., and T. Nakagawa and T. Uenaka are employees of Eisai co., Ltd. The other authors disclosed no potential conflicts of interest.

**Authors' Contributions**

Conception and design: T. Yamada, S. Takeuchi, S. Yano

Development of methodology: T. Yamada

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): T. Yamada, H. Mano

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): K. Kita, T. Nakagawa, T. Uenaka

Writing, review, and/or revision of the manuscript: T. Yamada, S. Yano

**References**


**Acknowledgments**

The authors thank Dr. Jeffrey A. Engelman (Massachusetts General Hospital Cancer Center) for providing the H3122 cells.

**Grant Support**

This study was supported by grants-in-aid for cancer research (T. Yamada, 23790902 and S. Yano, 21390256) and scientific research on innovative area “Integrative Research on Cancer Microenvironment Network” (S. Yano, 22112101A011) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received November 21, 2011; revised March 28, 2012; accepted April 17, 2012; published OnlineFirst May 2, 2012.


Paracrine Receptor Activation by Microenvironment Triggers Bypass Survival Signals and ALK Inhibitor Resistance in EML4-ALK Lung Cancer Cells

Tadaaki Yamada, Shinji Takeuchi, Junya Nakade, et al.

Clin Cancer Res  Published OnlineFirst May 2, 2012.

Updated version  Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-11-2972

Supplementary Material  Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2012/05/02/1078-0432.CCR-11-2972.DC1

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.